Brolucizumab is a follow-up to Novartis’ blockbuster AMD therapy Lucentis (ranibizumab), which has been competing toe-to-toe in the AMD market with Eylea for several years. Novartis reported ...
Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting ...
and compared Eylea versus Novartis' rival treatment Lucentis, and Roche's Avastin. The trial came about because of extensive off-label prescribing of Avastin against eye diseases such as age ...
The company states the acquisition will further MERIT’s service offerings, allowing for a seamless transition from ...
Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...
Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon's biosimilar to Lucentis ® 2 ... Formycon's biosimilar candidate to Eylea ® (aflibercept ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback